Search
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. … Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalVIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. … Other drug products with similar structure and function to Efmoroctocog alfa include [DB13999], which is produced by recombinant DNA technology and is identical in sequence to endogenously produced Factor
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Synonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261]
Letrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigationalLetrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. … [A190546] Letrozole was granted FDA approval on 25 July 1997.[L11623]
Mixtures: Kisqali Femara Co-pack, Kisqali Femara Co-packProducts: Co LetrozoleRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigational[L38814] The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawn[A229363] Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.